Feature | March 26, 2015

TAVR to Drive Rapid Market Growth for Prosthetic Valves

Market value projected to eclipse $3 billion by 2020

TAVR, transcatheter heart valves, GlobalData, TMVR

March 26, 2015 — Research and consulting firm GlobalData reported that the global market value for transcatheter heart valves will expand at a Compound Annual Growth Rate (CAGR) of 19.7 percent through 2020, reaching an approximate value of $3.02 billion.

The company’s report states that this is almost three times the projected value of the tissue heart valves market, which will increase at a much slower CAGR of 3.2 percent to just under $1.08 billion over the same period.

GlobalData’s forecast only considers aortic valve replacement, as there are not yet any approved transcatheter mitral valve replacement (TMVR) devices. The approval of TMVR devices will have a significant impact on this forecast, but early adoption rates are expected to be slow due to initial cost.

While surgical valves will hold a steady presence in the overall prosthetic valve market, transcatheter aortic valve replacement (TAVR) is expected to cannibalize a large portion of this market in the coming decade. As increasing competition drives down device costs, patients will subsequently have better access to minimally invasive treatment.

Premdharan Meyyan, GlobalData’s analyst covering medical devices, said that while first-generation devices have shown promising clinical outcomes to date, physicians have noted issues such as paravalvular regurgitation and a lack of repositionability.

Meyyan explained: “Transcatheter valves that are fully repositionable and retrievable address some of the main issues inherent in earlier products. Notable devices include Boston Scientific’s Lotus Valve System, Edwards Lifesciences’ Sapien 3, and Medtronic’s CoreValve Evolut R, the latter of which recently displayed a 6.5 percent improvement in all-cause mortality rate compared to open-heart surgery at the two-year mark.

“The adoption of these next-generation valves is expected to drive significant market growth, provided that clinical data continues to show positive mortality and morbidity outcomes for patients.”

The analyst added that as only high-risk or inoperable aortic valve disease patients are currently eligible for TAVR, more robust, long-term clinical data must be established before the treatment is offered to lower-risk patients.

“Until then, physicians will likely opt for the surgical option, as there is a multitude of clinical data proving efficacy. However, GlobalData believes it is likely that the indications for TAVR will expand and the technology will begin to dominate the surgical market over the forecast period,” Meyyan concluded.

For more information: www.globaldata.com

Related Content

Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
The ChordArt transcatheter mitral valve leaflet chord replacement system on X-ray, showing the anchoring sections of the artificial chord.

The ChordArt transcatheter mitral valve leaflet chord replacement system on X-ray, showing the anchoring sections of the artificial chord.

News | Heart Valve Technology| August 01, 2017
Aug.
Hitachi and West Virginia University Partner to Advance Left Ventricular Mechanical Function Evaluation
News | Cardiovascular Ultrasound| July 21, 2017
Hitachi Healthcare and the West Virginia University Heart and Vascular Institute announced the formation of a new...
Edwards Sapien 3 TAVR valve will be implanted in asymptomatic aortic stenosis patients in the EARLY TAVR Trial
Feature | Heart Valve Technology| July 14, 2017
July 14, 2017 — Morristown Medical Center, part of Atlantic Health System, has randomized the first patient in the wo
Ziosoft's PhyZiodynamics 4-D processing showing a replaced aortic valve

An example of Ziosoft's PhyZiodynamics 4-D processing showing a replaced aortic valve.

Technology | Computed Tomography (CT)| July 12, 2017
July 12, 2017 — At the 2017 annual meeting for the Society of Cardiovascular Computed Tomography (SCCT), Ziosoft show
Medtronic's CoreValve Evolut R gained FDA approval for intermediate risk patients

An illustration of the self-expanding CoreValve Evolut R TAVR valve half deployed in the aortic root.

Feature | Heart Valve Technology| July 10, 2017
The U.S. Food and Drug Administration (FDA) has cleared an additional indication to expand the use Medtronic's self-...
HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use
News | Annuloplasty Rings| July 05, 2017
July 5, 2017 — BioStable Science & Engineering Inc.
Novel Approach May Improve Valve Function in Some Patients

Image courtesy of Messas, et al. JACC Basic to Translational Medicine.

News | Heart Valve Technology| June 30, 2017
June 30, 2017 — Pulsed cavitation ultrasound can be used to remotely soften human degenerative calcified biosprosthet
Overlay Init